Introduction: We aimed to assess the relationships between the persistence of elevated circulating levels of hs-CRP, a powerful inflammatory marker, determined at 30 days after an acute myocardial infarction (AMI), and the characteristics of the pre-existing coronary lesions. Material and methods: The study included 83 consecutive patients 30 days post AMI, who were subjected to coronary angiography and primary PCI. The patients were divided into two groups according to their hsCRP levels at 30 days after AMI: group 1 included 35 low-risk patients, with hsCRP levels <2 mg/l, and group 2 included 48 high-risk patients, with hsCRP levels >2 mg/l. Results: Angiographic analysis revealed the presence of a multivascular disease in 48.5% of the patients in group 1 versus 72.9% of the patients in group 2 (p=0.037). The Syntax scores for groups 1 and 2 were 22.2 +/- 6.6 and 27.07+/-0.94, respectively (p=0.001), and these values were significantly correlated with the hsCRP values (r=0.56, p<0.0001). LAD culprit lesions were found in 47.9% of the patients in group 1 and 20% of the patients in group 2 (p=0.01), and 42.8% of the group 1 patients and 83.3% of the group 2 patients had at least one significant stenosis in the LAD (p=0.0002). The ejection fraction at 30 days was significantly lower in the patients with elevated levels of hsCRP (52.91+/-4.03 vs 49.04+/-5.74, p=0.001), showing an inverse correlation with hsCRP levels (r=-0.52, p<0.0001). Conclusions: A more severe coronary artery disease was associated with am increased inflammatory status in the postinfarction phase, as evidenced by the high levels of circulating hsCRP. hsCRP can help for risk stratification in post AMI patients by identifying the subsets of patients who are at risk based on persistent elevated circulating levels of hsCRP at 30 days after infarction.
1. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction.Cardiovasc Res. 2002 Jan;53(1):31-47. DOI: 10.1016/S0008-6363(01)00434-5
2. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000 Oct;343(16):1139-47. DOI: 10.1056/ NEJM200010193431602
3. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 1997 Aug;96(3):778-84. DOI: 10.1161/01.CIR.96.3.778
4. Ridker PM, Thuren T, Zalewski A, Libby P.Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).Am Heart J. 2011 Oct;162(4):597-605. DOI: 10.1016/j.ahj.2011.06.012
5. Bonvini RF, Hendiri T, Camenzind E. Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target? Eur Heart J Suppl.2005 Oct;7(- suppl I):I27-I36. DOI: 10.1093/eurheartj/sui077
6. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. CircRes. 2004 Jun;94(12):1543-53. DOI: 10.1161/01. RES.0000130526.20854.fa
7. Rioufol G, Zeller M, Dentan G, Laurent Y, L’Huillier I, Ravisy J, et al. Predictors and prognosis for complex coronary lesions in patients with acute myocardial infarction: data from RICO survey. Am Heart J. 2007 Aug;154(2):330-5. DOI: 10.1016/j.ahj.2007.04.013
8. Makrygiannis SS, Ampartzidou OS, Zairis MN, Patsourakos NG, Pitsavos C, Tousoulis D, et al. Prognostic usefulness of serial C-reactive protein measurements in ST-elevation acute myocardial infarction.Am J Cardiol. 2013 Jan 1;111(1):26-30. DOI: 10.1016/j.amjcard. 2012.08.041
9. Raposeiras-Roubín S, Barreiro Pardal C, Rodi-o Janeiro B, Abu-Assi E, García-Acu-a JM, González-Juanatey JR. High-sensitivity C-reactive protein is a predictor of in-hospital cardiac events in acute myocardial infarction independently of GRACE risk score.Angiology. 2012 Jan;63(1):30-4. DOI: 10.1177/0003319711406502
11. Brodie BR, Stuckey TD, Hansen C, VerSteeg DS, Muncy DB, Moore S, et al. Relation between electrocardiographic ST-segment resolution and early and late outcomes after primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2005 Feb;95(3):343-8. DOI: 10.1016/j.amjcard.2004.09.031
12. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002 Apr;105(16):1909-13. DOI: 10.1161/01.CIR.0000014683.52177.B5
13. Gibson CM, Kirtane AJ, Morrow DA, Palabrica TM, Murphy SA, Stone PH, et al. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30). Am Heart J. 2006 Oct;152(4):756-61. DOI: 10.1016/j. ahj.2006.04.016
14. Raposeiras Roubín S, Barreiro Pardal C, Roubín-Cami- a F, Ocaranza Sanchez R, Alvarez Castro E, ParadelaDobarro B, et al. High-sensitivity C-reactive protein predicts adverse outcomes after non-ST-segment elevation acute coronary syndrome regardless of GRACE risk score, but not after ST-segment elevation myocardial infarction.Rev Port Cardiol. 2013 Feb;32(2):117-22. DOI: 10.1016/j.repc.2012.05.026
15. Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, et al. Early inflammation and risk of longterm development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am CollCardiol. 2006 Mar;47(5):962-8. DOI: 10.1016/j.jacc.2005.10.055
16. Herrmann J, Lennon RJ, Barsness GW, Sandhu GS, Gulati R, Best PJ, et al. High sensitivity C-reactive protein and outcomes following percutaneous coronary intervention in contemporary practice. CircCardiovascInterv. 2012 Dec;5(6):783-90. DOI: 10.1161/CIRCINTERVENTIONS. 112.972182
17. Magadle R, Hertz I, Merlon H, Weiner P, Mohammedi I, Robert D. The relation between preprocedural C-reactive protein levels and early and late complications in patients with acute myocardial infarction undergoing interventional coronary angioplasty.ClinCardiol. 2004 Mar;27(3):163-8. DOI: 10.1002/clc.4960270314
18. Pietilä KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum - C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J. 1996 Sep;17(9):1345-9. DOI: 10.1093/oxfordjournals.eurheartj.a015068
19. Cağli KE, Topaloğlu S, Aras D, Günel EN, Ozlü MF, Uygur B, et al. The significance of admission hs-CRP in patients undergoing primary percutaneous intervention for acute myocardial infarction. Turk KardiyolDernArs. 2009 Jan;37(1):19-25.
20. Swiatkiewicz I, Kozinski M, MagielskiP. Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. Inflamm Res.2012 July;61(7):725-734. DOI: 10.1007/s00011-012-0466-2
21. Perlas TR., Te CG, Punzalan FE., Uy CC., Medldrick G. High Sensitivity CRP and Short-Term Cardiovascular Risk among Patients with Acute Myocardial Infarction: A Two-center Study. ActaMedPhilipp. 2012;46(3):64-68.